Skip to main content

Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers

Aug 28 (Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they would collaborate on a clinical trial to evaluate a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.